BioSET is a private, clinical stage orthobiologics company developing a new class of therapeutic peptides to improve bone and soft tissue repair. BioSET products combine chemically synthetic growth factors with procedure specific biomaterials to provide superior alternatives in orthopedic tissue grafting applications. The company’s lead clinical programs combine their B2A bone regeneration peptide with a resorbable ceramic bone substitute to offer substantial safety, efficacy, cost and patient benefits to currently available bone grafting alternatives. In addition to enhanced biologic bone regeneration, in combination with its large corporate partner, the company is developing their F2A synthetic growth factor into the next generation soft tissue graft for ligament and tendon repair in sports medicine applications.
For more information about BioSET, their clinical programs and their novel synthetic tissue regenerating peptides, contact Tom Roueche, President & CEO of BioSET at 301-795-6010 or troueche@biosetinc.com